206 related articles for article (PubMed ID: 25714032)
1. Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells.
Bofill-De Ros X; Villanueva E; Fillat C
Oncotarget; 2015 Mar; 6(8):6179-90. PubMed ID: 25714032
[TBL] [Abstract][Full Text] [Related]
2. miR-148a- and miR-216a-regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity.
Bofill-De Ros X; Gironella M; Fillat C
Mol Ther; 2014 Sep; 22(9):1665-77. PubMed ID: 24895996
[TBL] [Abstract][Full Text] [Related]
3. Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.
Rovira-Rigau M; Raimondi G; Marín MÁ; Gironella M; Alemany R; Fillat C
Mol Ther; 2019 Jan; 27(1):230-243. PubMed ID: 30341009
[TBL] [Abstract][Full Text] [Related]
4. A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirus.
José A; Rovira-Rigau M; Luna J; Giménez-Alejandre M; Vaquero E; García de la Torre B; Andreu D; Alemany R; Fillat C
J Control Release; 2014 Oct; 192():148-56. PubMed ID: 25037019
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
6. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
[TBL] [Abstract][Full Text] [Related]
7. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
8. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
11. Targeting human breast cancer cells by an oncolytic adenovirus using microRNA-targeting strategy.
Shayestehpour M; Moghim S; Salimi V; Jalilvand S; Yavarian J; Romani B; Mokhtari-Azad T
Virus Res; 2017 Aug; 240():207-214. PubMed ID: 28867494
[TBL] [Abstract][Full Text] [Related]
12. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
13. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D; Yanover E; Adam V; Sweeney K; Costas C; Lemoine NR; Halldén G
Clin Cancer Res; 2010 Jan; 16(2):541-53. PubMed ID: 20068104
[TBL] [Abstract][Full Text] [Related]
14. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
15. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
16. Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells.
Hodzic J; Sie D; Vermeulen A; van Beusechem VW
Hum Gene Ther; 2017 Sep; 28(9):766-780. PubMed ID: 28114818
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
Callegari E; Elamin BK; D'Abundo L; Falzoni S; Donvito G; Moshiri F; Milazzo M; Altavilla G; Giacomelli L; Fornari F; Hemminki A; Di Virgilio F; Gramantieri L; Negrini M; Sabbioni S
PLoS One; 2013; 8(9):e73964. PubMed ID: 24069256
[TBL] [Abstract][Full Text] [Related]
18. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R
Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo.
Rognoni E; Widmaier M; Haczek C; Mantwill K; Holzmüller R; Gansbacher B; Kolk A; Schuster T; Schmid RM; Saur D; Kaszubiak A; Lage H; Holm PS
Cancer Gene Ther; 2009 Oct; 16(10):753-63. PubMed ID: 19363467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
